Andrews, Joan M.
Eli Lilly (United States)
2 papers on CoChat
Most cited papers
- Verified
LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 42
- Verified
Abstract P5-19-13: clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer
Tolaney, S. M., Rosen, L. S., Beeram, M., Goldman, J. W., Gandhi, L., Tolcher, A. W., Papadopoulos, K. P., Rasco, D. W., Myrand, S. P., Kulanthaivel, P., et al. (2015) · Cancer Research
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free